This article focuses specifically on endometrial cancer, a cancer that begins in the lining of the uterus. In the United States, treatment planning now goes beyond naming the disease and selecting a standard protocol. Doctors use diagnosis, staging, pathology, and biomarker results to understand how aggressive the tumor may be and which therapies are more likely to help. That has led to more personalized care, especially for people with high-risk, advanced, or recurrent disease. This article is for informational purposes only and should not be considered medical advice. Please consult a qualified healthcare professional for personalized guidance and treatment.

How diagnosis and staging shape care

Diagnosis often starts after abnormal uterine bleeding, pelvic symptoms, or findings from imaging or routine gynecologic evaluation. A biopsy is usually needed to confirm whether cancer is present in the endometrium, which is the inner lining of the uterus. Once cancer is confirmed, staging helps show whether it is limited to the uterus or has spread to nearby tissue, lymph nodes, or distant organs. Staging may involve imaging, lab work, and surgical findings. This process is central to treatment decisions because early-stage disease is managed differently from advanced or recurrent cancer.

What surgery does in uterine oncology

Surgery remains the main first treatment for many patients with endometrial cancer. The standard operation often includes removal of the uterus, cervix, fallopian tubes, and ovaries, with lymph node assessment when needed. In many hospitals, minimally invasive techniques such as laparoscopy or robotic-assisted surgery are used when appropriate, which may support shorter hospital stays and recovery. Sentinel lymph node mapping has also become more common in uterine oncology because it can provide staging information while reducing the need for more extensive node removal in selected patients.

When radiation therapy is used

Radiation therapy is commonly considered after surgery when pathology shows features linked to a higher risk of recurrence. It may also be used in people who are not candidates for surgery or in cases where cancer returns. External beam radiation therapy treats a broader area in the pelvis, while vaginal brachytherapy delivers radiation more directly to the upper vagina, where recurrence can sometimes occur. Some patients need one form, and others need both. The choice depends on stage, grade, depth of invasion, lymphovascular involvement, and the overall pattern of risk seen after diagnosis.

Where chemotherapy fits today

Chemotherapy is often used when the disease is high grade, has spread beyond the uterus, or comes back after initial treatment. A commonly used regimen includes carboplatin and paclitaxel, though exact plans vary by pathology, prior treatment, and overall health. Chemotherapy matters because it circulates throughout the body and can address cancer cells beyond the original tumor site. In current practice, it may be given after surgery, together with other treatments, or for recurrent disease. Care teams also pay close attention to side effects such as fatigue, numbness, blood count changes, and nausea during therapy.

Immunotherapy and hormonal options

Newer treatment approaches have expanded beyond chemotherapy alone. Immunotherapy can be useful for selected patients, especially when biomarker testing shows mismatch repair deficiency or microsatellite instability, findings that may predict a stronger response to immune-based drugs. Hormonal therapy also remains important, particularly for certain slower-growing tumors that respond to estrogen- or progesterone-related pathways. It may be considered in recurrent disease, in some advanced cases, or when a less intensive treatment approach is appropriate. These options do not replace surgery or radiation in every setting, but they add flexibility and precision to modern therapy planning.

Why pathology and biomarker testing matter

Pathology is no longer limited to confirming that a uterine cancer exists. Modern pathology reports describe the tumor subtype, grade, depth of myometrial invasion, and whether the cancer involves lymphatic or vascular spaces. Biomarker testing adds another layer by identifying molecular features such as mismatch repair status, p53 abnormalities, and HER2 expression in selected cases. These details can affect prognosis and guide treatment choices, including whether immunotherapy or targeted treatment should be considered. In practical terms, pathology and biomarker results help doctors move from a one-size-fits-all plan to a strategy shaped by the biology of the tumor.

How combined treatment plans are evolving

One of the biggest changes in oncology is the move toward combination planning rather than relying on a single treatment type. A patient with early-stage disease may do well with surgery alone or surgery followed by limited radiation, while a patient with aggressive pathology may need chemotherapy, radiation, and closer molecular evaluation. Recurrent disease may lead to another shift, with immunotherapy, hormonal treatment, or other systemic approaches becoming more relevant. The newer model is less about replacing established therapies and more about using them in a more informed order based on diagnosis, staging, and tumor behavior.

Care for endometrial cancer is becoming more precise because doctors can now connect uterine pathology, staging, and biomarkers to specific treatment pathways. Surgery, radiation, chemotherapy, immunotherapy, and hormonal therapy each remain important, but their value depends on the exact features of the cancer. As a result, newer ways to treat this disease are defined not by a single breakthrough, but by better matching each therapy to the patient’s stage, tumor type, and molecular profile.